Cargando…

CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience

INTRODUCTION: Capecitabine-temozolomide (CAPTEM) has significant activity in patients (pts) with metastatic low grade pancreatic neuroendocrine tumors (NETs). However, there is limited data regarding its activity in pts with metastatic well-differentiated intermediate and high grade pancreatic and n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sahu, Arvind, Jefford, Michael, Lai-Kwon, Julia, Thai, Alesha, Hicks, Rodney J., Michael, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402194/ https://www.ncbi.nlm.nih.gov/pubmed/30915122 http://dx.doi.org/10.1155/2019/9032753

Ejemplares similares

Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
por: Thomas, Katharine, et al.
Publicado: (2020)

Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM
por: Ingenerf, Maria, et al.
Publicado: (2023)

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
por: Arrivi, Giulia, et al.
Publicado: (2022)

Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis
por: Lu, Yaoheng, et al.
Publicado: (2018)

Long-Term Follow-Up of Significant Improvement After CAPTEM Treatment for Rare Adrenocorticotropin-Producing Cardiac Neuroendocrine Tumor
por: Lu, Lin, et al.
Publicado: (2019)

Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience
por: Douangprachanh, Sathathone, et al.
Publicado: (2022)

Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol
por: Bongiovanni, Alberto, et al.
Publicado: (2020)

Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor
por: Williamson, Laura M., et al.
Publicado: (2019)

Clinicopathological Features of Primary Neuroendocrine Tumors of Gastrointestinal/Pancreatobiliary Tract With Emphasis on High-Grade (Grade 3) Well-Differentiated Neuroendocrine Tumors
por: Hashmi, Atif A, et al.
Publicado: (2021)

Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case
por: Manneh, Ray, et al.
Publicado: (2016)

Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature
por: Neychev, Vladimir, et al.
Publicado: (2017)

Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer
por: Faure, Marjorie, et al.
Publicado: (2017)

Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors
por: Das, Satya, et al.
Publicado: (2021)

Grade 3 well-differentiated neuroendocrine tumor of the rectum: a case report
por: Ito, Misato, et al.
Publicado: (2020)

Heart Failure in a Patient With Metastatic Well-Differentiated Neuroendocrine Tumor
por: Henderson, Amy, et al.
Publicado: (2023)

Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
por: Vijayvergia, Namrata, et al.
Publicado: (2020)

Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
por: Pellat, Anna, et al.
Publicado: (2020)

Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions
por: Pellat, Anna, et al.
Publicado: (2021)

Metastatic well-differentiated neuroendocrine carcinoma of the pancreas: case report and review of literature
por: Martin, Mersadies R, et al.
Publicado: (2009)

A practical proposal on treatment sequencing of metastatic well-differentiated neuroendocrine tumours
por: Perrier, Marine, et al.
Publicado: (2023)

Surgical treatment of intermediate to high grade thymic neuroendocrine neoplasms: case series of five patients and literature review
por: Huang, Chuan, et al.
Publicado: (2022)

Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort
por: Papantoniou, Dimitrios, et al.
Publicado: (2023)

Metastatic well differentiated serotonin-producing pancreatic neuroendocrine tumor with carcinoid heart disease: a case report
por: Kudelka, Matthew R., et al.
Publicado: (2023)

Neuroendocrine Tumor, Well Differentiated, of the Breast: A Relatively High-Grade Case in the Histological Subtype
por: Tajima, Shogo, et al.
Publicado: (2013)

A Well-Differentiated Grade-3 Neuroendocrine Tumor in the Ascending Colon: A Case Report
por: AlSaffar, Ali, et al.
Publicado: (2022)

Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms
por: La Rosa, Stefano
Publicado: (2021)

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
por: Kim, Su-Jung, et al.
Publicado: (2010)

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
por: Eads, Jennifer R, et al.
Publicado: (2023)

Prognostic differences in grading and metastatic lymph node pattern in patients with small bowel neuroendocrine tumors
por: Reinhard, Lisa, et al.
Publicado: (2023)

Isolated subcutaneous recurrence of high-grade neuroendocrine tumor of the cervix
por: Bos, Lia, et al.
Publicado: (2021)

Survivorship research for people with metastatic or advanced cancer: A time for action
por: Smith, Andrea L., et al.
Publicado: (2022)

Comparative genomics of high grade neuroendocrine carcinoma of the cervix
por: Hillman, R. Tyler, et al.
Publicado: (2020)

Classics to moderns in the intermediate grades
por: Agay, Denes
Publicado: (1962)

Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors
por: Kim, Min Jeong, et al.
Publicado: (2018)

Chronic venulectasias secondary to persistent flushing in the setting of a metastatic well-differentiated neuroendocrine tumor
por: Pope, Eleanor M., et al.
Publicado: (2022)

Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia
por: Abdelmalak, Rebecca, et al.
Publicado: (2021)

Implications of fluorodeoxyglucose uptake in low-intermediate grade metastatic neuroendocrine tumors from peptide receptor radionuclide therapy outcome viewpoint: A semi-quantitative standardized uptake value-based analysis
por: Adnan, Aadil, et al.
Publicado: (2019)

Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs
por: Park, Hyung Kyu, et al.
Publicado: (2023)

Changes in biodistribution on (68)Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
por: Cherk, Martin H., et al.
Publicado: (2018)

Low Grade Neuroendocrine Tumors of the Lung
por: Melosky, Barbara
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i296nv5bec01j5s9kqfqsegrbj